PerkinElmer
check quantity

OsteoSense 750EX Fluorescent Imaging Agent

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV10053EX
607.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

OsteoSense® 750EX is a targeted fluorescent in vivo bisphosphonate imaging agent. OsteoSense 750 EX images areas of microcalcifications and bone remodeling and enables imaging of bone growth and resorption. OsteoSense 750 EX fluorescent imaging agent can be used to measure the effects of therapeutic stimulation of bone growth. 

This agent can also be used to characterize bone remodeling associated with animal models of arthritis. OsteoSense 750 EX enables in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.

Specifications

Fluorescent Agent Type Targeted
Optical Imaging Classification Fluorescence Imaging
Product Brand Name OsteoSense
Quantity in a Package Amount 1.0 Units
Shipping Condition Ambient
Therapeutic Area Atherosclerosis, Arthritis, Oncology/Cancer
Unit Size 1 Vial (10 doses)
Wave Length 750 nm
Resources, Events & More
  • All

Flyer

Technical Note

OsteoSense 750 EX (Protocol)

OsteoSense 750 EX in vivo fluorescent imaging agent protocol

PDF 258 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB